A Phase 2 interventional study of Saroglitazar Magnesium 4 mg and Placebo in Nonalcoholic Fatty Liver Disease, sponsored by Zydus Therapeutics Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 443rd largest by enrollment of the 460 interventional ones that give a count, is one of 38 that started in 2022, is one of 192 in phase 2, and was the 433rd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 38 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in People Living with Human Immunodeficiency Virus (HIV) in the US
The four participants enrolled on version 3.0 protocol were terminated as the primary endpoint was revised from biopsy to an imaging-based approach in the subsequent protocol version 4.0. These changes were done due to recruiting challenges pertaining to biopsy. However, no participants were enrolled in the revised protocol (version 4.0) as, by then the decision to terminate the study was taken by the Sponsor considering the modifications in the internal R\&D focus and a revised commercialization strategy.
The version 3.0 protocol is dated 02/Jun/2022.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants whose Visit 2 , AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%.
Note: These participants will be required to have a third value measured at-least one week after V2, to assess for a trend. If the third value shows a continued increase ≥10% compared to the Visit 2 values, the participant is considered ineligible for randomization.
Any of the following laboratory values at screening:
Unstable cardiovascular disease, including:
Pregnancy-related exclusions, include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks)
Drug: Saroglitazar Magnesium 4 mg
Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks).
Drug: Placebo
Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of treatment (24 weeks).
Subjects randomized to Placebo arm will receive Placebo treatment until the duration of treatment (24 weeks).
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Hepatic Fat Content Measured by MRI Proton Density Fat Fraction (MRI PDFF)
Change from baseline in hepatic fat content
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Reduction of Hepatic Fat Content as Measured by MRI PDFF.
Proportion of participants with reduction of at least 30% in hepatic fat content from baseline
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE .
Change from baseline in Liver Stiffness Measurement
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE
Change from baseline in Continuous Controlled Attenuation Parameter
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/Vibration-controlled Transient Elastography (VCTE).
Change from baseline in Fibroscan-aspartate aminotransferase (FAST) score
Time frame: Week 24/EOT
To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis
Change from baseline in plasma pro-collagen type 3 (PRO-C3) levels
Time frame: Week 24/EOT
To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis
Change from baseline in Fibrois-4 index (FIB-4) This index is based on age, platelet count, ALT level, and AST level. FIB-4 was calculated using the following formula: FIB4 = (Age (years) x AST (U/L))/(Platelet count (10\^9/L) x √ALT (U/L)). A decrease in FIB-4 represents a positive outcome. A FIB-4 Index of \<1.45 indicates none to moderate fibrosis and an Index of \>3.25 indicates advanced fibrosis.
Time frame: Week 24/EOT
To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis
Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis
Time frame: Week 24/EOT
To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis
Change from baseline in Nonalcoholic fatty liver disease Fibrosis Score (NFS) The NFS is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. NFS was calculated using the following formula: NAFLD fibrosis score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A decrease in NFS score represents a positive outcome. An NFS score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis.
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Liver Enzyme
Change from baseline in liver enzyme parameters (ALT and AST)
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Lipid Profile
Change from baseline in triglyceride \[TG), high-density lipoprotein \[HDL\], low-density lipoprotein \[LDL\], very low-density lipoprotein \[VLDL\], total cholesterol, and non-HDL cholesterol
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Fasting Glucose
Change from baseline in fasting plasma glucose (FPG)
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.
Change from baseline in body weight
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.
Change from baseline in BMI
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.
Change from baseline in hip circumference and minimum waist circumference
Time frame: Week 24/EOT
To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Health-related Quality of Life Scores Measured by Short Form-36 (SF-36) Questionnaire.
Change from baseline in SF-36 Questionnaire mental (MCS) and physical components scores (PCS). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status.
Time frame: Week 24/EOT.
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo
Number of Participants with Adverse Events. We have included data for Treatment emergent adverse events (TEAEs) only. TEAEs are those AEs that occur after administration of the study drug.
Time frame: From baseline to Week 28
| Milestone | Saroglitazar Magnesium 4 mg | Placebo Arm |
|---|---|---|
| Started | 3 | 1 |
| Completed | 0 | 0 |
| Not completed | 3 | 1 |
| Withdrew: Study terminated | 3 | 1 |
Change from baseline in hepatic fat content
No measurements were reported for this outcome.
Proportion of participants with reduction of at least 30% in hepatic fat content from baseline
No measurements were reported for this outcome.
Change from baseline in Liver Stiffness Measurement
No measurements were reported for this outcome.
Change from baseline in Continuous Controlled Attenuation Parameter
No measurements were reported for this outcome.
Change from baseline in Fibroscan-aspartate aminotransferase (FAST) score
No measurements were reported for this outcome.
Change from baseline in plasma pro-collagen type 3 (PRO-C3) levels
No measurements were reported for this outcome.
Change from baseline in Fibrois-4 index (FIB-4) This index is based on age, platelet count, ALT level, and AST level. FIB-4 was calculated using the following formula: FIB4 = (Age (years) x AST (U/L))/(Platelet count (10\^9/L) x √ALT (U/L)). A decrease in FIB-4 represents a positive outcome. A FIB-4 Index of \<1.45 indicates none to moderate fibrosis and an Index of \>3.25 indicates advanced fibrosis.
No measurements were reported for this outcome.
Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis
No measurements were reported for this outcome.
Change from baseline in Nonalcoholic fatty liver disease Fibrosis Score (NFS) The NFS is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. NFS was calculated using the following formula: NAFLD fibrosis score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A decrease in NFS score represents a positive outcome. An NFS score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis.
No measurements were reported for this outcome.
Change from baseline in liver enzyme parameters (ALT and AST)
No measurements were reported for this outcome.
Change from baseline in triglyceride \[TG), high-density lipoprotein \[HDL\], low-density lipoprotein \[LDL\], very low-density lipoprotein \[VLDL\], total cholesterol, and non-HDL cholesterol
No measurements were reported for this outcome.
Change from baseline in fasting plasma glucose (FPG)
No measurements were reported for this outcome.
Change from baseline in body weight
No measurements were reported for this outcome.
Change from baseline in BMI
No measurements were reported for this outcome.
Change from baseline in hip circumference and minimum waist circumference
No measurements were reported for this outcome.
Change from baseline in SF-36 Questionnaire mental (MCS) and physical components scores (PCS). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status.
No measurements were reported for this outcome.
Number of Participants with Adverse Events. We have included data for Treatment emergent adverse events (TEAEs) only. TEAEs are those AEs that occur after administration of the study drug.
| Participants | Saroglitazar Magnesium 4 mg | Placebo Arm |
|---|---|---|
| Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo | 0 | 0 |
Collected over From Baseline to Week 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 4 mg | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Placebo Arm | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Saroglitazar Magnesium 4 mg | Placebo Arm |
|---|---|---|
| Upper Respiratory tract InfectionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/1 |
Safety Population
| Age, Categorical(Participants) | Saroglitazar Magnesium 4 mg | Placebo Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 3 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 4 mg | Placebo Arm | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 4 mg | Placebo Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Saroglitazar Magnesium 4 mg | Placebo Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Saroglitazar Magnesium 4 mg | Placebo Arm | Total |
|---|---|---|---|
| United States | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Oct 2023, 9 months.
Results were first posted in Jul 2025, 1 year 9 months after primary completion. A results delay was requested in Oct 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar
Non-alcoholic Fatty Liver Disease →